ArticleBreast (Edinburgh, Scotland)2018
Partial breast irradiation: The time is there!
Article in Breast (Edinburgh, Scotland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Comment on
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The conventionally fractionated partial breast irradiation (PBI) IMPORT LOW trial represents the perfect example of how an adequate selection of patients led to a minimal local relapse rate for patients. Coles and colleagues, demonstrated a 5-year non-inferiority local relapse rate for PBI compared to standard whole breast irradiation, together with a significant reduction in terms of breast toxicity using a conventional radiation technique implementable worldwide. Most of enrolled patients had early stage node negative, grade1-2, oestrogen receptor positive, human epidermal growth factor receptor 2 negative tumours. An exponential decrease in term of local relapse rate was observed from the first published PBI studies. The new high-level evidence provided by these results clearly demonstrates that while toxicity and cosmetic outcome concerns are strongly dependent on the technique, the efficacy of PBI is closely related to the adequate choice of patients. Upcoming data from several studies and from matured follow up of the published ones will be critical to confirm if also accelerated PBI could be accepted as a standard alternative to whole breast irradiation. However, we feel that IMPORT LOW inclusion criteria, together with tumour biology should be definitively integrated in the decision-making process.
Indexed as
Identifiers
29289822What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.